A further marked upregulation of ACE2 has been identified in COVID-19 patients with chronic pulmonary comorbidities, pulmonary fibrosis, asthma, lung cancer, chronic obstructive pulmonary disease (COPD), diabetes, and hypertension [61]. Here, ACE2 is linked to lung carcinoma.